AstraZeneca expands ARTEMIDE-Lung02 to 1,160 patients, extends completion to 2030
The Phase 3 trial testing rilvegostomig against pembrolizumab in squamous NSCLC grew its enrollment target 32% and pushed its primary completion date more than a year, changes that widen the eventual overall-survival readout rather than signal trouble.
Executive Summary
- AstraZeneca enlarged its head-to-head Phase 3 trial of rilvegostomig against pembrolizumab in squamous non-small cell lung cancer and extended the study's completion timeline by well over a year.
- The scale of the enrollment increase falls inside the range operational risk models treat as ordinary trial management, not a sign of struggling recruitment or a design problem.
- The trial is built to answer whether AstraZeneca's PD-1/TIGIT bispecific can outperform the market-leading PD-1 monoclonal on overall survival, the benchmark that determines whether it can displace incumbent first-line therapy.
- Rilvegostomig enters a field where multiple sponsors, including Merck, AbbVie and Roche, run direct PD-1-targeted comparators in NSCLC, meaning the mechanism is validated but not yet resolved in AstraZeneca's favor.
- With completion now guided to mid-2030, the readout sits years away, and the trial's larger population is the more relevant fact for judging what a future result will support.
The change
ARTEMIDE-Lung02 (NCT06692738), AstraZeneca's global Phase 3 trial pitting rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, against pembrolizumab plus platinum-based chemotherapy in first-line squamous NSCLC, raised its enrollment target from 880 to 1,160 patients, a 32% increase, according to a July 14, 2026 registry update. The same update pushed the primary completion date from February 5, 2029 to July 1, 2030, a shift of roughly 511 cumulative days. The trial's title and eligibility criteria were also revised in the same update to include locally advanced disease alongside metastatic disease, expanding the population beyond the original metastatic-only scope. NCT06692738+1A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Jul 14, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Reading the scale
An enrollment increase of this size sits within the range the operational risk model treats as routine, which flags changes at 20% or more as significant and 40% or more as high; a 32% increase does not cross into the high-risk band. The trial has been Recruiting since December 2024 and enrolls across the United States, China and Japan. AstraZeneca's own track record in this drug class supports reading the change as scope expansion rather than distress: the company has completed 91% of its trials overall and 97% of its trials in the checkpoint-receptor class specifically, covering 29 prior studies. NCT06692738A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738
The endpoint bar
The trial's co-primary endpoints are overall survival and progression-free survival, measured against radiological progression under RECIST 1.1 criteria (a standard tumor-measurement framework), with a follow-up window extending to approximately six years. Because pembrolizumab is the approved, incumbent PD-1 backbone in this setting, the trial's design frames rilvegostomig's task as replication or improvement on an established survival benchmark rather than establishing a new mechanism from scratch, since checkpoint blockade is already validated in squamous NSCLC. No results have posted on the trial's public record. NCT06692738A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738
The competitive field
AstraZeneca runs rilvegostomig across eight active NSCLC trials in total, spanning adjuvant, first-line monotherapy, and combination settings, indicating a broad development program built around this single asset. Direct comparators sharing the PD-1 target and mechanism class include Merck's pembrolizumab program (NCT06623422), AbbVie's livmoniplimab (NCT06236438), and Roche's divarasib (NCT05789082), all active in Phase 2 or Phase 3 NSCLC studies. The nearest same-modality precedent is ivonescimab, a PD-1 bispecific antibody from a separate sponsor also in Phase 2 testing in NSCLC, placing rilvegostomig in a field where the bispecific format itself, not just the PD-1 target, has more than one active competitor. NCT06692738A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.